CLINICAL EFFICACY Oral Telithromycin George Rochester, PhD, CCRN Statistical Reviewer Division of Biometrics III Division of Anti-infective Drug Products.

Slides:

Advertisements

Similar presentations

CQ Deng, PhD PPD Development Research Triangle Park, NC 27560

Advertisements

Antimicrobial Prescribing in the Management of COPD

Chest Infections Lawrence Pike.

Acute Otitis Media Trials: Evolution of Guidance Janice Soreth, M.D. Division of Anti-Infective Drug Products January 30, 2001.

1 Issues in Selection of Deltas in Non-Inferiority Trials : Acute Bacterial Meningitis and Hospital- Acquired Pneumonia John H. Powers, M.D. Medical Officer.

Augmentin® ES Clinical Microbiology Review

Microbiologic Surrogate Endpoints in Clinical Trials-IDSA FDA/IDSA/ISAP Workshop April 15, 2004 Sheldon L. Kaplan, MD Baylor College of Medicine Texas.

Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.

Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.

Design of Clinical Trials of Antibiotic Therapy for Acute Otitis Media

Luveris ® New Drug Application ( ) Kate Meaker, M.S. Statistical Reviewer Division of Biometrics II Kate Meaker, M.S. Statistical Reviewer Division.

IDSA / ISAP / FDA Workshop on Antimicrobial Drug Development Update 2004 Edward Cox, MD MPH ODE IV Center for Drug Evaluation and Research US Food and.

1 Selection of  in Clinical Trials of Antimicrobial Therapy - Acute Exacerbation of Chronic Bronchitis Susan D. Thompson, M.D. February 19, 2002.

Acute Bacterial Rhinosinusitis. Brief Background Typically follows viral infection Dx is by clinical manifestations Streptococcus pneumoniae, Haemophilus.

1 Data from Studies in One Indication Supporting Studies in a Different Indication March 5, 2003 Anti Infective Drugs Advisory Committee Meeting Edward.

NDA# Histamine Dihydrochloride FDA Review December 13, 2000.

Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.

Pulmonary and Allergy Drugs Advisory Committee January 17, 2002 Pulmonary and Allergy Drugs Advisory Committee Meeting Gaithersburg, Maryland January 17,

Development of Antibiotics for Otitis Media: Past, Present, and Future Janice Soreth, M.D. Director Division of Anti-Infective Drug Products.

Augmentin ES  for acute otitis media Mamodikoe Makhene, M.D. Prepared for Anti-infectives Advisory Committee meeting January 30, 2001.

CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.

Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.

1 SNDA Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.

Issues with Effectiveness, Resistance and Ethics in Antimicrobial Clinical Trials How We Can Do Better Issues with Effectiveness, Resistance and Ethics.

1 Statistics in Drug Development Mark Rothmann, Ph. D.* Division of Biometrics I Food and Drug Administration * The views expressed here are those of the.

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 FDA Presentation Advair Diskus 500/50 Carol Bosken, MD, ScM, MPH Medical Officer Division of Pulmonary.

1 Exploring Alternative Antibiotic Treatment Regimens: Methodology and Implications Dr. Tabish Hazir MASCOT Study Group 2 nd ICIUM Conference 2004.

August 20, 2003FDA Antiviral Drugs Advisory Committee Meeting 1 Statistical Considerations for Topical Microbicide Phase 2 and 3 Trial Designs: A Regulatory.

1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.

1 Observations from Past Approvals for Acute Bacterial Sinusitis Janice Pohlman, M.D. AIDAC Meeting, October 29, 2003.

1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,

Clinical Trials of Acute Otitis Media John Alexander, M.D., M.P.H. Anti-Infective Drugs Advisory Committee November 7, 2001.

1 International Society for CNS Clinical Trials and Methodology FDA Advisory Committee Meeting Proposed Requirement for Long-Term Data to Support Initial.

General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,

Acute Otitis Media: Lessons Learned Thomas Smith, M.D. Division of Anti-Infective Drug Products.

Center for Drug Evaluation and Research March 6, 2005 Bacteremia and Endocarditis: Products and Guidance Janice Soreth, MD Director Division of Anti-Infective.

Anti-Infective Drugs Advisory Committee Meeting September 12, Factive® (gemifloxacin) Proposed for the treatment of Acute Bacterial Sinusitis Oscient.

Ketek  (telithromycin) NDA Background Janice Soreth, M.D. Director Division of Anti-Infective Drug Products CDER/FDA.

Catheter-Related Blood Stream Infections A Phase 2 Randomized, Controlled Trial of Dalbavancin vs. Vancomycin Tim Henkel, MD, PhD Executive VP and Chief.

1 Recent Advances in Provision of Primary Care in the Public Sector: Is 3 Days of Oral Antibiotic Therapy Enough for Treatment of Ambulatory Pneumonia?

Acute Bacterial Otitis Media Summary and Charge to the Committee Renata Albrecht, M.D. Division of Special Pathogen and Immunologic Drug Products ODEIV,

Ketek ™ (Telithromycin) NDA Efficacy Review John Alexander, M.D., M.P.H. Medical Team Leader Division of Anti-Infective Drug Products.

CS-1 Regulatory Considerations: PDD Indication for Exelon ® (rivastigmine) Martina Struck, PhD Senior Associate Director Drug Regulatory Affairs Novartis.

David M. Shlaes Anti-infectives Consulting, LLC Stonington, CT Participation sponsored by: Nabriva, Vienna, AU Novexel, Romainville, FR Consulting relationships.

SNDA # GLIADEL® WAFER (Polifeprosan 20 with Carmustine Implant) APPLICANT: GUILFORD PHARMACEUTICALS ODAC: December 6, 2001 Medical Reviewer: Alla.

Study Designs for Acute Otitis Media: What can each design tell us? C. George Rochester, Ph.D. Anti-Infective Advisory Committee Meeting, July 11, 2002.

1 Zithromax  (Azithromycin) Oral Suspension Single-Dose & 3-day Treatment of Acute Otitis Media Anti-Infective Drugs Advisory Committee November 7, 2001.

Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.

Lancet Respir Med 2013; 1: 199–209 R4.신재령 / Prof. 박명재

Amoxicillin for Acute Rhinosinusitis A Randomized Controlled Trial Garbutt JM, Banister C, Spitznagel E, Piccirillo JF. JAMA 2012;307(7): Prof.

The American Journal of Gastroenterology, October 2014, Volume 109:1595–1602 Prof. 장재영 /R3 김다래.

COPD SPUTUM PRODUCERS AND THE INFLUENCE ON ANTIBIOTIC RESISTANCE Sarah Thurston PhD student.

Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Johannes M.A. Daniels; Dominic snijders;

SNDA ETHYOL FOR RADIATION INDUCED XEROSTOMIA.

Moxifloxacin Development in TB Dr. Martin Springsklee VP, Therapeutic Area Head, Clinical Development Anti-Infectives Bayer HealthCare AG GATB Annual Stakeholder.

Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.

Meta-Analysis of a Possible Signal of Increased Mortality Associated with Cefepime Use Peter W. Kim, Yu-te Wu, Charles Cooper, George Rochester, Thamban.

Addition of Inhaled Tobramycin to Ciprofloxacin for Acute Exacerbations of Pseudomonas aeruginosa Infection in Adult Bronchiectasis* Diana Bilton, MD;

A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis

Barrios C et al. SABCS 2009;Abstract 46.

Ketolides: A New Class of Antibacterial Agents for Treatment of Community-Acquired Respiratory Tract Infections in a Primary Care Setting Jeffrey Paul.

Single-dose extended-release oral azithromycin vs

Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia C. Carbon, S. Moola,

Issues in TB Drug Development: A Regulatory Perspective

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

J. Garau Clinical Microbiology and Infection

Community-acquired pneumonia in adults

Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis S.R. Norrby, J. Quinn, M. Rangaraju,

Aparna Raychaudhuri, Ph. D

Presentation transcript:

CLINICAL EFFICACY Oral Telithromycin George Rochester, PhD, CCRN Statistical Reviewer Division of Biometrics III Division of Anti-infective Drug Products

2 Outline Phase III clinical database Censored data Clinical or bacteriologic efficacy by indication Overall conclusion

3 Phase III Clinical Database by Type of Study and Indication

4 Censored Data Four investigators were censored by the FDA. Total number of patients excluded were 186. Patients were excluded from all indications except T/P. Both FDA’s and Sponsor’s analyses excluded all subjects from the censored sites.

5 Phase III Clinical Data Dosing of interest was for 5 days for AECB, AMS and T/P, and 7-10 days for CAP. All studies had a designated test-of-cure (TOC) window for assessing the clinical or bacteriologic response. TOC varied by indication but was always specified in the study protocol.

6 Definition of Populations The primary efficacy populations for CAP, AECB and AMS are mITT and PPc. mITT: All randomized subjects who met disease definition and received at least one dose of study drug. PPc: mITT subjects minus those with major protocol violations.

Community Acquired Pneumonia

8 CAP: Clinical Response -TOC TelithromycinComparators95% C.I. %(N)% (%) PPc (149)90(152) (-2.1, 11.1) (162)88(156) (-7.9, 7.5) (80)94(86) (-13.6, 5.2) mITT (199)79(205) (-0.5, 15.3) (204)81(212) (-9.9, 6.5) (100)86(104) (-14.7, 7.5) 1 Amoxicillin, 2 Clarithromycin, 3 Trovafloxacin

Acute Exacerbation Of Chronic Bronchitis

10 AECB Definitions Inclusion: Documented history of chronic bronchitis, FEV 1 /FVC < 70% (tests made in the previous 12 months) Presentation:  cough,  sputum volume,  sputum purulence, and/or dyspnea Cure: resolution of all symptoms and no subsequent antimicrobial therapy at TOC

11 AECB: Clinical Response -TOC Telithromycin 5 days Comparators 10 days 95% C.I. %(N)% (%) PPc (115)82(112) (-6.4, 14.3) (140)83(142) (-5.7, 12.4) mITT (160)78(160) (-6.3, 12.6) (182)72(191) (-3.5, 15.1) 1 Augmentin, 2 Cefuroxime axetil

ACUTE MAXILLARY SINUSITIS

13 Sinusitis: Clinical Response -TOC Telithromycin 5 day Comparators 10 day 95% C.I. %(N)% (%) PPc (146)75(137)(-9.9, 11.7) (189)82(89)(-7.1, 13.4) mITT (201)68(202)(-8.2, 10.9) (240)72(116)(-2.2, 18.2) 1 Augmentin, 2 Cefuroxime

GROUP A  -HEMOLYTIC STREPTOCOCCAL TONSILLITIS/PHARYNGITIS

15 T/P: Regulatory Considerations Penicillin is the gold standard comparator Primary efficacy is based on microbiologic eradication Any product with an absolute eradication rate of < 85% in the PP population should not be considered first line therapy

16 T/P: Conclusion T/P is a mild disease Targeted population is typically children Many alternative therapies Insufficient evidence of activity against erythromycin resistant S. pyogenes Risk/Benefit must be considered

17 Overall Conclusion FDA’s efficacy analyses are consistent with those of the applicant. Adequate, well-controlled trials must demonstrate safety and efficacy.